Background
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in humans, [1] yet current treatment options for AF have suboptimal efficacy. The limitations of current treatments for atrial fibrillation are likely secondary to incomplete understanding of the mechanisms underlying the development of atrial fibrillation. This emphasizes the need for better understanding the mechanisms of AF in order to develop more mechanism-directed AF therapies.
Myocardial calcium cycling dysregulation is an important mechanism for arrhythmogenic cardiac alternans in the ventricle and is a postulated mechanism of AF. [2, 3] Mathematical models have predicted cardiac alternans as an important mechanism for the development of AF and perhaps more important, recent data in humans has shown that cardiac alternans precedes the onset of AF. [4] [5] [6] [7] We previously established that SERCA2a expression is an important regulator of calciumalternans (Ca-ALT) in the ventricle. [8] Specifically, we found that increased SERCA2a expression in both the normal and failing ventricle increases the HR threshold (i.e. decreased susceptibility) for Ca-ALT with a concomitant reduction in inducible ventricular arrhythmias. Based on these data we hypothesized that SERCA2a overexpression will decrease cardiac alternans and arrhythmias in the atrium. To test our hypothesis, we modulated SERCA2a expression/ function by SERCA2a overexpression using an adenoviral vector (Ad.SERCA2a) or with SERCA2a inhibition using Thapsigargin in isolated rat atrial myocytes.
Methods
Experiments were carried out in accordance with the United States Public Health Service guidelines for the care and use of laboratory animals. IACUC approval at Case Western Reserve University "Gene Therapy for cardiac alternans" protocol number 2013-0131. Adult rat isolated atrial myocytes where divided into three treatment groups 1) Control, 2) SERCA2a overexpression (Ad.SERCA2a) and 3) SERCA2a inhibition (Thapsigargin, 1μm).
Gene Delivery
Adenoviral vectors consisting of the CMV immediate/early promoter/enhancer, rabbit SERCA2a (Ad.SERCA2a) or no gene of interest then a second cassette for GFP reporter (Ad.GFP) were utilized as previously described. [8] In-vivo gene transfer was performed in a subset of male Sprague-Dawley rats using modified cross-clamping method as previously described. [8, 9] In-vitro gene transfer was performed by incubating isolated rat myocytes with Ad.GFP (vector control) or Ad.SERCA2a.GFP for 24 hours.
Isolation of rat atrial myocytes
Myocytes were isolated from rat hearts using modified enzymatic dispersion technique described previously. [10] The main modification was that to digest the hearts the enzyme solution containing collagenase II (0.8mg/ml) was perfused for 20 min. 
Protein expression
Isolated atrial myocytes were divided into 2 dishes for Ad.SERCA2a or Ad.GFP infection. Paired samples were collected 24 hours post-gene transfer. Cells were spun down at 1.5rpm for 3 min and rinsed 3x in cold PBS. Cells were then lysed in RIPA lysis buffer plus complete protease inhibitor cocktail (Roche) and homogenized using a 25-gauge needle on ice. Lysates were run on 4-15% TGX gels (Bio-Rad) and blotted for SERCA2a (1:1000, Dr. Periasamy, Ohio State University), RyR (1:800, Affinity Bioreagents), Phospholamban (1:1000, Santa Cruz), NCX (1:1000, Swant) and actin (1:1000, Sigma-Aldrich). Comparisons were made within each animal (Rat 1 Ad.GFP myocytes vs. Ad.SERCA2a myocyte level of SERCA2a expression etc.).
In-vivo arrhythmia susceptibility 3-5 days post-gene transfer, animals were anesthetized (Ketamine, Xylazine). Once fully anesthetized, a 5F quad catheter was advanced down the esophagus and 3 limb leads were attached (right arm, left arm, left leg). ECG recordings were recorded at baseline and pacing was verified before burst pacing to assess atrial arrhythmia susceptibility. Pacing protocols included 10-15 seconds of burst pacing followed by halted pacing to assess the rhythm. Burst pacing was performed at 160ms to 50ms decrementing by 10ms intervals to assess atrial arrhythmia susceptibility.
Data Analysis & Statistics
Ca-ALT was measured by calculating the difference in amplitude on 2 consecutive beats, normalized to one of the beats and was defined to be present when Ca-ALT exceeded 10% of Ca 2+ transient amplitude, as described previously.
[12] Statistical differences were calculated using student's t test and Chi-squared tests when appropriate.
Results

Increased SERCA2a expression does not suppress cardiac alternans in the atria
Adenoviral SERCA2a gene transfer in isolated rat atrial myocytes increased SERCA2a protein expression when compared to control myocytes (p<0.05, Fig 1) . Importantly, we did not observe changes in other calcium handling proteins such as Na + -Ca 2+ exchanger (NCX), ryanodine receptor (RyR) or phospholamban. As predicted, SERCA2a significantly reduced Ca . Surprisingly, we did not observe a difference in Ca-ALT thresholds between control myocytes and Ad.SERCA2a expressing atrial myocytes (p = 0.63, Fig 3B/3C ). In contrast, Ad. SERCA2a expressing ventricular myocytes did significantly increase Ca-ALT thresholds compared to control myocytes (p = 0.002, Fig 3D) . This suggested that SERCA2a might not play a role in atrial alternans in the absence of disease.
SERCA2a inhibition does not enhance cardiac alternans in the atria
Based on the observation that SERCA2a overexpression does not contribute to atrial cardiac alternans we investigated the role of SERCA2a inhibition on cardiac alternans in the atria. Inhibition of SERCA2a with thapsigargin significantly increased calcium transient duration (p = 0.04), decreased the rate of calcium reuptake (τ, p = 0.02) and there was a nonsignificant trend toward increased diastolic calcium (p = 0.07, Fig 4) . Consistent with our finding using SERCA2a overexpression, SERCA2a inhibition also did not alter Ca-ALT threshold when compared to control (p = 0.74, Fig 5) . Taken together these results suggest that SERCA2a plays little role in atrial alternans in the absence of disease. 
SERCA2a increases arrhythmogenic substrates in isolated atrial myocytes
Interestingly, SERCA2a overexpression in atrial myocytes significantly increased premature SR Ca 2+ release events (4 of 14 myocytes) when compared to control (0 of 11 myocytes, p = 0.04, Fig 6) . Furthermore, Ad.SERCA2a expressing myocytes significantly increased SR calcium content (Fig 6B p<0.05) , suggesting a likely mechanism for increased incidence of spontaneous Ca 2+ release events in SERCA2a overexpressing atrial myocytes.
SERCA2a overexpression may increase atrial arrhythmias in-vivo
Because we observed significant increases in arrhythmogenic substrates in isolated atrial myocytes, we wanted to test if Ad.SERCA2a gene transfer enhanced atrial arrhythmias in-vivo. We performed in-vivo gene transfer of Ad.SERCA2a in male Sprague-Dawley rats. Following 3-5 days post-gene transfer, a pacing catheter was advanced down the esophagus of anesthetized rats for transesophageal atrial pacing (Fig 7a) . Atrial burst pacing induced atrial fibrillation Representative Ca 2+ tracings of control (n = 11) and SERCA2a overexpression (Ad.SERCA2a, n = 12) atrial myocytes is depicted in A. Surprisingly, there was no difference in Ca 2+ alternans threshold between control and Ad.SERCA2a expressing myocytes (B/C). Both began Ca-ALT as stimulation rate was increased from 480 bpm to 540 bpm. In contrast to atrial myocytes, ventricular myocytes overexpressing SERCA2a (n = 12) significantly increased Ca 2+ alternans threshold compared to controls (n = 11, p = 0.002).
doi:10.1371/journal.pone.0137359.g003
SERCA2a Does Not Contribute to Atrial Ca 2+ Alternans (Fig 7b) in 20% of rats following Ad.SERCA2a gene transfer compared to no inducible atrial arrhythmias in Ad.GFP treated control animals (Fig 7c, p = 0.20) .
Discussion
Cardiac alternans in the atria has been postulated as an important mechanism of atrial fibrillation in humans. [6] Previously, we demonstrated that SERCA2a is an important molecular SERCA2a Does Not Contribute to Atrial Ca 2+ Alternans mechanism for the genesis of cardiac alternans in the ventricle. However, the role of SERCA2a in the development of cardiac alternans in the atria is less clear. A key finding of the present investigation is that in contrast to ventricular myocytes, SERCA2a does not modulate cardiac alternans in the atria. Furthermore, we found that SERCA2a overexpression can increase arrhythmogenic triggers in the atria, presumably from increased SR Ca 2+ loading. These data suggest that in contrast to the ventricle, modulation of SERCA2a expression/activity in atrial myocytes does not alter susceptibility to cardiac alternans and may be arrhythmogenic secondary to increased premature SR Ca 2+ release events. which was restored to baseline with SERCA2a gene transfer. [13] It is possible that differences in SR Ca 2+ cycling kinetics exist between isolated adult atrial myocytes and HL-1 myocytes used by Tsai et al, accounting for the differences in the role of SERCA2a in modulating cardiac alternans. Further stretch induces hypertrophic signaling in addition to alterations in SERCA2a expression in atrial myocytes, which may contribute to changes in SR Ca 2+ cycling kinetics between the two studies. [14] The strength of our study is that we utilized native atrial myocytes in contrast to immortal cell lines. Overall our data emphasize that SERCA2a does not contribute to atrial Ca-ALT under normal physiologic conditions. In agreement with our findings atrial computer models predict increased SERCA2a uptake would not produce alterations in atrial calcium alternans. [15] Li et al. showed increased SERCA2a overexpression did not result in increased atrial arrhythmias. Since we observed significant increases in premature SR Ca 2+ release events, we sought to determine if SERCA2a overexpression resulted in increased arrhythmias in vivo. In vivo gene transfer was accomplished through using aortic-pulmonary cross-clamp techniques while Ad.SERCA2a (n = 5) or Ad.GFP (n = 4 control) was injected. 3-5 days post gene-transfer, we transesophageally burst paced (catheter in grey) the atria as depicted in A. Standard limb leads were used to record ECGs. Pacing is depicted as S 1 . Burst pacing did not stimulate AF in control rats (B, top panel) but did stimulate AF in some Ad.SERCA2a rats (B, bottom panel). We observed 20% of animals to have AF with Ad.SERCA2a expression; however this was non-significant. Summary data is shown on the right in B. SERCA2a activity loaded the SR and maintained stable calcium waves without affecting Ca-ALT. However, this model also predicts SERCA2a inhibition would alter Ca-ALT through depletion of SR content limiting SR calcium release. [15] In the present study we did not observe alterations in Ca-ALT using Thapsigargin to inhibit SERCA2a activity. It is possible the degree of SR Ca 2+ content depletion predicted by the model was greater than that produced by Thapsigargin in our study. Secondly, the model utilized by Li et al. was first developed based on ventricular calcium wave propagation and then altered to lack t-tubules. Structural differences between ventricular and atrial myocytes may also explain why atrial SERCA2a overexpression would not alter atrial Ca-ALT thresholds. Small mammal and pathophysiologic atrial myocytes (i.e. heart failure, dilated atrium in large mammals) differ from ventricular myocytes in that they lack t-tubules. [17] [18] [19] This produces a fundamental change in the mechanism of electromechanical coupling. In contrast to ventricular myocytes, junctional SR-calcium propagates as a wave toward nonjunctional-SR, stimulating calcium release toward the central part of an atrial cell. Therefore, calcium waves are predicted to be strongly dependent upon junctional-SR content in the atrium. Overexpressing SERCA2a would serve to overload the SR, as shown with our data, but would not inhibit a calcium wave toward the central region of cell. This would allow for a cell to have minimal beat-to-beat variability in calcium cycling with increasing heart rates without the development of Ca-ALT.
The role of RyR2 in atrial alternans and arrhythmogenesis has been highlighted in several studies. Xie et al recently found that atrial 'leaky' RyR promoted Ca-ALT, Ca 2+ waves and atrial arrhythmias. [20] Similarly, it was shown that RyR refractoriness lead to atrial Ca-ALT in a model of human atrial cells and rabbit atrial cells. [21, 22] Others have also highlighted the importance of CaMKII hyperphosphorylation of RyR leading to Ca 2+ dysregulation in AF. [23, 24] Finally, it appears that in addition to Ca 2+ dysregulation, structural remodeling or fibrosis significantly contributes to the development of alternans induced arrhythmias, [25] suggesting that sustained atrial arrhythmias require both structural and electrophysiologic remodeling. Despite the role RyR2 and atrial remodeling plays in atrial alternans, we importantly demonstrated ventricular SERCA2a-mediated alternans is absent in atrial cells.
SERCA2a overexpression in the atrium increases arrhythmia triggers
In the present study we observed that atrial SERCA2a overexpression increased premature SR Ca 2+ release events, most likely due to increased SR Ca 2+ content. Increased SR calcium content greatly affects SR calcium release events and promotes spontaneous calcium release events. [26, 27] Further, increased release of Ca 2+ from the SR is an important trigger for atrial fibrillation, particularly in heart failure.
[28] Therefore, we assessed if SERCA2a overexpression would increase atrial arrhythmias in-vivo. We observed a nonsignificant trend for increased inducible atrial arrhythmias in rats exposed to Ad.SERCA2a gene transfer compared to Ad.GFP control animals, suggesting atrial SERCA2a overexpression may increase AF arrhythmogenic triggers. We did not assess if SERCA2a overexpression increased atrial premature beats, which may have occurred as we caused increased SR content. Liang et al 2008 found isolated atrial myocytes from AF and normal patients had no difference in frequency of Ca 2+ sparks, [29] suggesting frequency of Ca 2+ sparks does not enhance atrial arrhythmias. Further we examined normal atria without any significant atrial remodeling. Sustained AF is dependent upon both electrical and structural remodeling such as atrial fibrosis, allowing for slowed conduction and reentry to develop. [30] In heart failure hearts, there is substantial atrial structural remodeling, suggesting SERCA2a overexpression in heart failure atria may be more proarrhythmic than we observed.
Study Limitations
Limitations should be considered in extrapolating our data. Our studies were performed in normal atrial myocytes where SERCA2a function is not altered as in disease settings. However, we establish that SERCA2a does not modulate Ca-ALT in normal atrial myocytes suggesting SERCA2a function is not a key player in the development of Ca-ALT in the atrium as it is in the ventricular myocardium.
Conclusions
Our data provide new insights into the potential mechanisms of atrial alternans and ultimately atrial fibrillation. In particular, we suggest that SERCA2a is not a key regulator of calcium alternans in the atrium, suggesting that RyR may be a more important determinant of atrial alternans. Importantly, SERCA2a overexpression in atrial myocytes may increase spontaneous SR Ca 2+ release. In normal atrium, enhanced Ca 2+ release events may not be proarrhythmic, but in remodeled atria such as in heart failure enhanced spontaneous SR Ca 2+ release could prove to enhance the development of AF.
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